Currency In USD
| Previous Close | 28.51 |
| Open | 28.5 |
| Day High | 29.23 |
| Day Low | 27.6 |
| 52-Week High | 39.53 |
| 52-Week Low | 14.39 |
| Volume | 188,414 |
| Average Volume | 204,016 |
| Market Cap | 526.64M |
| PE | -6.26 |
| EPS | -4.46 |
| Moving Average 50 Days | 32.42 |
| Moving Average 200 Days | 27.67 |
| Change | -0.6 |
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
GlobeNewswire Inc.
Feb 23, 2026 9:01 PM GMT
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the act
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
GlobeNewswire Inc.
Feb 11, 2026 9:01 PM GMT
WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the act
Tectonic Therapeutic to Participate in December Investor Conferences
GlobeNewswire Inc.
Dec 01, 2025 1:00 PM GMT
WATERTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the act